184 related articles for article (PubMed ID: 28418731)
1. Why Do Some Concentrated Insulins Maintain Their Pharmacokinetics/Pharmacodynamics Profile?
Hood RC
Diabetes Technol Ther; 2017 Apr; 19(4):203-205. PubMed ID: 28418731
[No Abstract] [Full Text] [Related]
2. Concentrated insulins in current clinical practice.
Schloot NC; Hood RC; Corrigan SM; Panek RL; Heise T
Diabetes Res Clin Pract; 2019 Feb; 148():93-101. PubMed ID: 30583034
[TBL] [Abstract][Full Text] [Related]
3. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
[TBL] [Abstract][Full Text] [Related]
4. [New insulin types in type 1 diabetes mellitus].
Mesa J
Med Clin (Barc); 2015 Jul; 145(2):70-5. PubMed ID: 25200067
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous injection of hyaluronidase with recombinant human insulin compared with insulin lispro in type 1 diabetes.
Garg SK; Buse JB; Skyler JS; Vaughn DE; Muchmore DB
Diabetes Obes Metab; 2014 Nov; 16(11):1065-9. PubMed ID: 24840317
[TBL] [Abstract][Full Text] [Related]
6. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects.
Sinha VP; Choi SL; Soon DK; Mace KF; Yeo KP; Lim ST; Howey DC
J Clin Pharmacol; 2014 Jul; 54(7):792-9. PubMed ID: 24504686
[TBL] [Abstract][Full Text] [Related]
7. The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation.
Monnier L; Owens DR; Bolli GB
Diabetes Metab; 2016 Apr; 42(2):77-9. PubMed ID: 26688145
[No Abstract] [Full Text] [Related]
8. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
9. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
10. Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.
Bailey TS; Pettus J; Roussel R; Schmider W; Maroccia M; Nassr N; Klein O; Bolli GB; Dahmen R
Diabetes Metab; 2018 Feb; 44(1):15-21. PubMed ID: 29153485
[TBL] [Abstract][Full Text] [Related]
11. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl E; Owen DR
Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
[No Abstract] [Full Text] [Related]
12. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
[TBL] [Abstract][Full Text] [Related]
13. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
14. Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs.
Dungan KM; Buse JB; Herman WH; Arakaki RF; Jiang HH; Jacobson JG; Fahrbach JL
Diabetes Res Clin Pract; 2012 Jun; 96(3):e66-9. PubMed ID: 22421598
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
[TBL] [Abstract][Full Text] [Related]
16. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
18. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
19. Mixing insulin lispro and ultralente insulin.
Bastyr EJ; Holcombe JH; Anderson JH; Clore JN
Diabetes Care; 1997 Jun; 20(6):1047-8. PubMed ID: 9167130
[No Abstract] [Full Text] [Related]
20. Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
Al-Qaissi A; Papageorgiou M; Javed Z; Heise T; Rigby AS; Garrett AT; Hepburn D; Kilpatrick ES; Atkin SL; Sathyapalan T
Diabetes Obes Metab; 2019 Mar; 21(3):569-574. PubMed ID: 30311402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
